AZ12756122

exemple 117 from WO2008075070A1, synthesized at AstraZeneca Sulfonamide derivatives for therapeutic use as fatty acid synthase inhibitors

General

Type : Sulfonamide, Piperidine, Cyanide, Sulfur Compound

Chemical_Nomenclature : N-[5-[4-(4-cyanophenyl)piperidine-1-carbonyl]-2,4-dimethylphenyl]propane-1-sulfonamide

Canonical SMILES : CCCS(=O)(=O)NC1=C(C=C(C(=C1)C(=O)N2CCC(CC2)C3=CC=C(C=C3)C#N)C)C

InChI : InChI=1S\/C24H29N3O3S\/c1-4-13-31(29,30)26-23-15-22(17(2)14-18(23)3)24(28)27-11-9-21(10-12-27)20-7-5-19(16-25)6-8-20\/h5-8,14-15,21,26H,4,9-13H2,1-3H3

InChIKey : KMMFOIYEUUZOOG-UHFFFAOYSA-N

Other name(s) : SCHEMBL4175642


MW : 439.6

Formula : C24H29N3O3S

CAS_number :

PubChem : 57666876

UniChem : KMMFOIYEUUZOOG-UHFFFAOYSA-N

Target

Families : AZ12756122 ligand of proteins in family
Thioesterase

Protein :
human-FASN

References (2)

Title : AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models - Polonio-Alcala_2022_Biomed.Pharmacother_156_113942
Author(s) : Polonio-Alcala E , Porta R , Ruiz-Martinez S , Vasquez-Dongo C , Relat J , Bosch-Barrera J , Ciurana J , Puig T
Ref : Biomed Pharmacother , 156 :113942 , 2022
PubMedID: 36411628